Purpose Bio is developing proprietary novel therapeutics to treat metabolic syndrome diseases. 

Our first focused indications are NAFLD: Non-Alcoholic Fatty Liver Disease and Hyperlipidemia. 

100 Million adults in the U.S suffer from NAFLD and 60 Million adults in the U.S with Hyperlipidemia, are either intolerant or refuse to take traditional lipid lowering medicines, due to adverse side effects. 

NAFLD is an unmet need, becoming the world's most growing epidemic.